33.8 F
New York
Thursday, November 30, 2023
    HomeMarket NewsThe FDA's Positive Feedback Propels Hoth Therapeutics' Stock as HT-KIT Drug Progresses

    The FDA’s Positive Feedback Propels Hoth Therapeutics’ Stock as HT-KIT Drug Progresses

    Actionable Trade Ideas

    always free

    Shares of Hoth Therapeutics (NASDAQ:HOTH) surged by 6% during early trading following the company’s announcement of receiving affirmative feedback from the FDA regarding the proposed development plan for its oncology drug candidate, HT-KIT.

    In an official statement, Hoth revealed that it held discussions with the FDA before filing its Investigational Drug Application for the drug. The meeting aimed to assess the suitability of the 505(b)(1) pathway for the product, the sufficiency of referenced nonclinical information for the application, the proposed development plan to support the IND, and any potential filing issues the FDA might raise concerning the product.

    The biotech company outlined its intention to proceed with pre-IND activities as scheduled, leveraging the insight gained from the FDA’s feedback. Hoth is dedicated to developing the drug for treating AdvSM, or advanced systemic mastocytosis, a promising medical pursuit.

    Notably, the product has secured orphan drug designation from the FDA for its efficacy in treating mastocytosis.

    Unlocking Potential: Hoth Therapeutics’ Ongoing Endeavor

    Swing Trading Ideas and Market Commentary

    Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

    Explore More

    Weekly In-Depth Market Analysis and Actionable Trade Ideas

    Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.

    Related Articles